Antengene (HKG:6996) received the $60 million upfront payment from UCB under their exclusive licensing agreement for ATG-201, according to a Hong Kong bourse filing Monday.
The licensing agreement, announced in March, grants UCB exclusive global rights to develop and commercialize ATG-201, a CD19/CD3 bispecific T-cell engager antibody.
The company said the payment strengthens its cash position and will support the advancement of its drug pipeline.